OncoMatch/Clinical Trials/NCT07317414
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Is NCT07317414 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab combined with bevacizumab combined with β- alanine and Atezolizumab combined with bevacizumab for hepatocellular carcinoma.
Treatment: Atezolizumab combined with bevacizumab combined with β- alanine · Atezolizumab combined with bevacizumab — This study is a prospective, randomized controlled study on nutritional support and metabolic regulation. It assesses the safety, compliance, and improvement of metabolic/physical-related indicators when using β-alanine within the specified dose range as dietary supplementation, in addition to the standard first-line treatment. The anti-tumor efficacy (ORR, PFS, OS) is the exploratory endpoint.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE B (NOT ELIGIBLE FOR THERAPEUTIC SURGERY), BCLC STAGE C (NO DISTANT METASTASIS OR LYMPH NODE METASTASIS) (BCLC)
BCLC stage C, with no distant metastasis or lymph node metastasis, or BCLC stage B, who are not eligible for therapeutic surgery
Prior therapy
Cannot have received: local or systemic anti-tumor treatment
Who have previously received local or systemic anti-tumor treatment, or undergone liver transplantation
Cannot have received: liver transplantation
Who have previously...undergone liver transplantation
Cannot have received: radiotherapy
Exception: within 3 weeks prior to the first administration of the drug
Received radiotherapy within 3 weeks prior to the first administration of the drug
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5×10^9/L, platelet count ≥ 50×10^9/L, hemoglobin ≥ 90g/L
Kidney function
Serum creatinine ≤ 1.5×ULN, or creatinine clearance rate ≥ 50 mL/min (Cockcroft-Gault), urine protein < 2+; if urine protein ≥ 2+, 24-hour urine protein quantification < 1g
Liver function
Serum total bilirubin ≤ 3×ULN; ALT and AST ≤ 5×ULN; serum albumin ≥ 28 g/L; alkaline phosphatase ≤ 5×ULN; after conventional liver-protective treatment meets the above standards and can be stable for at least 1 week as evaluated by the investigator
The functions of the important organs should meet the following requirements: ... see full text for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify